|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:abstractText |
Blockade of the CTLA-4 and PD-1 inhibitory pathways in T cells via the administration of neutralizing antibodies at the time of interleukin (IL)-15 therapy markedly enhanced the survival of tumor-bearing mice as compared with those receiving IL-15 alone or IL-15 in combination with just one of the antibodies.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neutralizing,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA-4 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Ctla4 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-15,
http://linkedlifedata.com/resource/pubmed/chemical/PD-1 antigen, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5917-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21037024-Animals,
pubmed-meshheading:21037024-Antibodies, Neutralizing,
pubmed-meshheading:21037024-Antigens, CD,
pubmed-meshheading:21037024-Antigens, Differentiation,
pubmed-meshheading:21037024-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21037024-CTLA-4 Antigen,
pubmed-meshheading:21037024-Cell Line, Tumor,
pubmed-meshheading:21037024-Disease Models, Animal,
pubmed-meshheading:21037024-Drug Evaluation, Preclinical,
pubmed-meshheading:21037024-Drug Synergism,
pubmed-meshheading:21037024-Immune Tolerance,
pubmed-meshheading:21037024-Immunotherapy,
pubmed-meshheading:21037024-Interleukin-15,
pubmed-meshheading:21037024-Mice,
pubmed-meshheading:21037024-Models, Biological,
pubmed-meshheading:21037024-Neoplasm Metastasis,
pubmed-meshheading:21037024-Neoplasms,
pubmed-meshheading:21037024-Signal Transduction,
pubmed-meshheading:21037024-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Braking bad: blockade of inhibitory pathways improves interleukin-15 therapy.
|
|
pubmed:affiliation |
Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210-1228, USA. william.carson@osumc.edu
|
|
pubmed:publicationType |
Journal Article,
Comment
|
